82640-04-8 Usage
Description
Raloxifene hydrochloride, also known as Evista, is a nonsteroidal, selective estrogen receptor modulator (SERM). It is a light-yellow solid that is insoluble in water. Raloxifene hydrochloride is used for its antiosteoporotic properties and has been shown to reduce the risk of developing breast cancer. It was initially developed as keoxifene for breast cancer and prostatic hypertrophy but was later launched as Evista for the prevention of postmenopausal osteoporosis. Raloxifene hydrochloride is a pharmaceutical secondary standard used in quality control for pharmaceutical laboratories and manufacturers.
Uses
Used in Pharmaceutical Industry:
Raloxifene hydrochloride is used as a nonsteroidal, selective estrogen receptor modulator (SERM) for the prevention of postmenopausal osteoporosis. It helps to impede bone loss and reduce the risk of developing breast cancer.
Used in Quality Control:
Raloxifene hydrochloride is used as a pharmaceutical secondary standard for application in quality control, providing a convenient and cost-effective alternative to the preparation of in-house working standards.
Used in Mass Spectrometry:
Labeled Raloxifene hydrochloride is used as an internal standard for the quantification of Raloxifene by gas chromatography (GC) or liquid chromatography (LC) mass spectrometry.
Potential Future Applications:
Raloxifene hydrochloride has several extensions planned for different uses, such as growth disorder, obesity, colon tumor, and skin atrophy.
Biochem/physiol Actions
Raloxifene is a selective estrogen receptor modulator (SERM); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.
Clinical Use
Treatment and prevention of osteoporosis in post
menopausal women
Drug interactions
Potentially hazardous interactions with other drugs
Anticoagulants: antagonism of anticoagulant effect of
coumarins.
Colestyramine: reduced absorption of raloxifene -
avoid.
Metabolism
Raloxifene undergoes extensive first pass metabolism
to the glucuronide conjugates: raloxifene-4'-
glucuronide, raloxifene-6-glucuronide, and raloxifene-6,
4′-diglucuronide.
Raloxifene undergoes enterohepatic recycling, and is
excreted almost entirely in the faeces. Less than 6% of
dose is excreted in the urine.
references
[1] obach rs.potent inhibition of human liver aldehyde oxidase by raloxifene.
Check Digit Verification of cas no
The CAS Registry Mumber 82640-04-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,6,4 and 0 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 82640-04:
(7*8)+(6*2)+(5*6)+(4*4)+(3*0)+(2*0)+(1*4)=118
118 % 10 = 8
So 82640-04-8 is a valid CAS Registry Number.
InChI:InChI=1/C28H29NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,26,28,30-31H,1-3,14-17H2
82640-04-8Relevant articles and documents
Preparation method of raloxifene hydrochloride and intermediate thereof
-
, (2020/06/02)
The preparation method comprises the following steps: preparing a raloxifene hydrochloride precursor (intermediate 2) from 1-{4-[2-(piperidine-1-yl)ethyoxyl]phenyl}-2-(2-sulfydryl-4-methoxyphenyl)ethanone (intermediate 1) and 4-methoxybenzoyl halide, performing demethylation protection, and preparing raloxifene hydrochloride from the demethylated raloxifene hydrochloride precursor and hydrochloricacid. Herein, the intermediate 1 is generated by removing benzyl protection from an intermediate 3 (1-{4-[2-(piperidine-1-yl)ethoxy]phenyl}-2-(2-benzylthio-4-methoxyphenyl)ethanone) in trifluoroacetic acid through a reaction; (3-methoxyphenyl) benzyl sulfide is oxidized to generate a sulfoxide compound, and then the sulfoxide compound reacts with 1-[2-(4-ethynylphenoxy)ethyl]piperidine to generate an intermediate 3. The method has the advantages of mild reaction conditions, few side reactions, high yield, cheap reagent raw materials, easy recovery and easy preparation, and is suitable for industrial large-scale production.
PREPARATION OF RALOXIFENE AND ITS SALTS
-
Page/Page column 7; 8, (2011/04/14)
The invention provides processes for the preparation of pure raloxifene or its salts, involving hydrolyzing 6-methylsulfonyloxy-2-[(4-methylsulfonyloxy)-phenyl]-3-[4(2-(piperidinyl)ethoxy)benzoyl]benzothiophene hydrochloride, using an aqueous base.
A process for preparing benzo[b]thiophene derivatives
-
Page/Page column 34, (2011/06/10)
The present invention relates in general to the field of organic chemistry, and in particular to the preparation of benzo[b]thiophene derivatives. These benzo[b]thiophene derivatives are useful as intermediates in the synthesis of pharmaceutically active agents such as raloxifene or derivatives thereof.